文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

新冠疫苗对Delta变异株感染有效性的系统综述与Meta分析第二期中期结果

Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the Delta (B.1.617.2) variant: second interim results of a living systematic review and meta-analysis, 1 January to 25 August 2021.
PubMed 文献 · Euro Surveill · 2021-01-01

Delta变异株已成为SARS-CoV-2优势株,该活系统综述与Meta分析汇总17项研究的新冠疫苗有效性(VE)数据。合并VE对无症状感染为63.1%(95%CI:40.9-76.9),对有症状感染为75.7%(95%CI:69.3-80.8),对住院为90.9%(95%CI:84.5-94.7)。与Alpha变异株相比,对轻症结局的VE降低10-20%,但对重症COVID-19完全维持。

要点

  • 合并VE:无症状感染63.1%,有症状感染75.7%,住院90.9%。
  • 与Alpha相比,对轻症结局VE降低10-20%。
  • 对重症COVID-19的VE完全维持。

核心结论

  • 新冠疫苗对Delta变异株感染的有症状感染和住院具有保护效果,对重症保护完全维持。

研究设计与样本

  • 活系统综述与Meta分析,汇总17项研究新冠疫苗对不同结局的有效性,检索时间2021年1月1日至8月25日。

主要发现

  • 合并VE对无症状感染为63.1%(95%CI:40.9-76.9)。
  • 合并VE对有症状感染为75.7%(95%CI:69.3-80.8)。
  • 合并VE对住院为90.9%(95%CI:84.5-94.7)。
  • 与Alpha变异株相比,对轻症结局的VE降低10-20%,但对重症COVID-19完全维持。

临床怎么用

  • 应继续推进新冠疫苗接种以预防Delta变异株所致有症状感染和住院,尤其降低重症风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Delta variant has become the dominant strain of SARS-CoV-2. We summarised the evidence on COVID-19 vaccine effectiveness (VE) identified in 17 studies that investigated VE against different endpoints. Pooled VE was 63.1% (95% confidence interval (CI): 40.9-76.9) against asymptomatic infection, 75.7% (95% CI: 69.3-80.8) against symptomatic infection and 90.9% (95% CI: 84.5-94.7) against hospitalisation. Compared with the Alpha variant, VE against mild outcomes was reduced by 10-20%, but fully maintained against severe COVID-19.

来源:Euro Surveill,查看原文。版权归原作者所有。

引用

  1. Harder T, Külper-Schiek W, Reda S, et al. Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the Delta (B.1.617.2) variant: second interim results of a living systematic review and meta-analysis, 1 January to 25 August 2021. Euro Surveill. 2021. PMID: 34651577. doi:10.2807/1560-7917.ES.2021.26.41.2100920

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。